for the ESCAPE Trial Consortium and the 4C Study Group IMPORTANCE Conventional methods to diagnose and monitor chronic kidney disease (CKD) in children, such as creatinine level and cystatin C-derived estimated glomerular filtration rate (eGFR) and assessment of proteinuria in spot or timed urine samples, are of limited value in identifying patients at risk of progressive kidney function loss. Serum soluble urokinase receptor (suPAR) levels strongly predict incident CKD stage 3 in adults.
C hronic kidney disease (CKD) in children is associated with significant comorbidities, compromising life expectancy, quality of life, and psychosocial integration during childhood and early adult life. 1 3 as the first effective renoprotective strategy in pediatric CKD. Post hoc analyses and observational studies have identified additional modifiable conditions that effect the rate of deterioration in kidney function, such as metabolic acidosis and vitamin D deficiency. 4, 5 A growing body of preclinical and clinical research is evaluating novel approaches to pharmacological nephroprotection that may become available for children with CKD in the foreseeable future. 6, 7 The individual rate of eGFR loss in children is highly variable, in part because of the heterogeneity of underlying renal diseases and the differential effect of age and possibly sex. However, progression rates vary widely even within individual age and disease groups, indicating a need for informative prognostic biomarkers. Estimation of the glomerular filtration rate from serum creatinine level and determination of proteinuria have traditionally been used to identify patients at heightened risk of developing progressive CKD. 1, 2 Although a variety of novel urinary biomarkers of tubular injury, including neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, and renal liver-type fatty acid binding protein, have been proposed to improve the accuracy of predicting the development of CKD, they have not been found to improve predictive models of CKD based on traditional laboratory tests in adults. 8, 9 Recently, soluble urokinase receptor (suPAR), a marker of immune activation involved in the pathogenesis of focal segmental glomerulosclerosis, 10 was found to be strongly predictive of CKD beyond traditional clinical measures in adult patients. 11 These findings have subsequently been confirmed in 2 other adult cohorts. 12, 13 Whether suPAR levels are associated with decline in renal function in the pediatric CKD population is unknown. In this report, we present a post hoc analysis of a combined cohort consisting of pediatric patients with CKD enrolled in 2 studies: the observational 4C Study (Cardiovascular Comorbidity in Children with Chronic Kidney Disease Study; NCT01046448) 14, 15 and the ESCAPE Trial. 3 We tested the hypothesis that high serum suPAR levels may be a biomarker in children with CKD that is associated with a more rapid decline in renal function.
Methods
This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement checklist for cohort studies (https://www.strobe-statement.org).
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Study Population
The effect of suPAR serum levels on eGFR decline in children with CKD was analyzed by combining 2 of the largest pediatric CKD cohorts: the 4C Study 14, 15 and the ESCAPE Trial. 3 Both studies were designed and performed according to the Declaration of Helsinki. The protocols were approved by the central ethics committee of the Heidelberg University Medical Faculty and by each local ethical committee. Written informed consent, including future use of stored specimens, was obtained from the parents and adolescents, and oral informed assent was obtained from younger children. Patients were eligible for inclusion in this study if (1) they were participants in the 4C Study or ESCAPE Trial, (2) data on renal disease progression during follow-up were available, and (3) serum samples were available for determination of suPAR concentration.
In the 4C Study, 704 patients were enrolled to study the causes and consequences of cardiovascular disease in children and adolescents aged 6 to 17 years with CKD stage 3B or 4 (eGFR, 15-45 mL/min/1.73 m 2 ) prior to dialysis or transplantation. The children were observed prospectively, with clinical assessments every 6 months and collection of blood and urine samples. 14, 15 The ESCAPE Trial was an investigator-initiated randomized clinical trial evaluating the effect of intensified blood pressure control on renal disease progression. A total of 468 children aged 3 to 17 years with CKD stage 2 to 4 (GFR, 15 to 80 mL/min/1.73 m 2 ) were enrolled. All patients received the angiotensin-converting enzyme inhibitor ramipril in a fixed dose of 6 mg/m 2 /d and additional antihypertensive medication, where appropriate, targeting a blood pressure goal of either below the 50th or between the 50th and 95th blood pressure percentile. Children were followed up prospectively, with clinical assessments every 2 months and blood and urine collection. 3 
Laboratory Assessment
In both studies, urinary analyses and renal function parameters were analyzed centrally, using standard laboratory techniques to measure the serum and urinary concentrations of creatinine and urinary protein excretion, as described previously. 3, 14, 15 In the 4C Study, eGFR was determined using cystatin C clearance and proteinuria was measured as the albumin:creatinine ratio in spot urines. In the ESCAPE Trial, eGFR was calculated using the Schwartz formula, and proteinuria was measured as the protein:creatinine ratio in a 24-hour urine
Key Points
Question Are elevated serum soluble urokinase receptor (suPAR) levels associated with renal disease progression in children with chronic kidney disease?
Findings In this cohort study of 898 children, 5-year end point-free renal survival was 64.5% in children with suPAR levels in the lowest quartile compared with 35.9% in those with suPAR levels in the highest quartile. In patients with baseline estimated glomerular filtration rates greater than 40 mL/min/1.73 m 2 , higher log-transformed suPAR levels were associated with a higher risk of chronic kidney disease progression after adjusting for conventional risk factors.
Meaning High suPAR levels may identify children at risk for future chronic kidney disease.
sample. Serum suPAR levels were measured with a commercially available enzyme-linked immunosorbent assay kit (suPARnostic kit; ViroGates), as described previously.
11 The intra-assay and interassay variability for the suPAR determinations were 2.75% and 9.17%, respectively. We have demonstrated that serum suPAR levels are stable and reproducible in samples stored for more than 5 years at −70°C.
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Statistical Analysis
Baseline characteristics of the whole sample and stratified by study (4C vs ESCAPE) are described by means and SDs, medians and interquartile ranges, and frequencies. Proteinuria was defined as positive or negative by either urinary protein excretion of 0.5 g/g creatinine or greater (ESCAPE Trial) or albumin excretion of 50 mg/g creatinine or greater (4C Study). The influence of sex, diagnoses, initial eGFR, and age on logtransformed suPAR levels was analyzed by a multivariable linear model. In addition, the association was adjusted for study (ESCAPE Trial vs 4C Study).
The primary end point in this study was renal survival, defined as a composite of 50% loss of GFR that persisted for at least 1 month, the start of renal replacement therapy, or an eGFR less than 10 mL/min/1.73 m 2 . If a 50% reduction in eGFR occurred between 2 study visits, interpolation was used to determine the time of the event. Kaplan-Meier curves stratified by quartiles of the suPAR levels are presented. Cox proportional regression models were applied to evaluate associations between baseline covariate levels and time to composite event. Three models were considered, which all included sex, age, proteinuria, systolic blood pressure, and renal diagnoses as covariates as well as study as a strata variable. In model 1, eGFR was added to the set of 5 basic covariates; in model 2, the log-transformed baseline suPAR level was added; and in model 3, both eGFR and the log-transformed baseline suPAR level were added to the basic covariates. Quality of the models was compared based on the Akaike information criterion (AIC), with lower values indicating a better fit. The AIC value is the expected, relative distance between the fitted model and the unknown true mechanism that generated the observed data. Model fits were compared by transformation of AIC to Akaike weights. 17 Akaike weights can be interpreted as the probability that the respective model is the best model. Additionally, hazard ratios for renal survival for high suPAR levels (ie, greater than the median) vs low suPAR levels were analyzed. Covariates included in the model were baseline eGFR, age, systolic blood pressure, standard deviation score, sex, proteinuria (categorized as proteinuria yes/ no), and diagnosis. In every model, the interaction of suPAR with the respective subgroup factor was included, and the χ 2 P value is reported. All P values are 2-tailed, and significance was set at P < .05. Furthermore, sensitivity analyses using different eGFR cutoff values were performed to determine whether the association between suPAR level and the primary end point varied according to baseline eGFR. Based on previous studies, 11, 18 we used an eGFR cutoff of 40 mL/min/ 1.73 m 2 to examine the differential association between suPAR level and eGFR decline in patients with and without severe renal dysfunction. 
Results
Cohort Description
Determinants of suPAR Concentrations
The median (interquartile range) suPAR concentration was 5.658 (4.610-7.053) pg/mL in this study, much higher than the 2.082 pg/mL seen in healthy control participants. 19 A breakdown of clinical and biochemical characteristics by suPAR distribution quartile is given in eTable 2 in the Supplement. In multivariable analysis, log suPAR concentrations were inversely associated with eGFR (−0.009; SD, 0.001; P < .001) but were not significantly associated with sex (female, 0.042; SD, 0.022; P = .06) or age (−0.005; SD, 0.003; P = .09). Additionally, they were not influenced by the type of renal disease.
suPAR Level and Renal Survival
Across all patients, 5-year renal survival was 35.9% (95% CI, 28.7-43.0) in children with suPAR levels in the highest quartile compared with 64.5% (95% CI, 57.4-71.7) in those in the lowest quartile (P < .001) (Figure 1) . In multivariable analysis, older age, the presence of proteinuria, higher systolic blood pressure, glomerular and tubulointerstitial disorders, and the initial eGFR were associated with a significantly higher likelihood of reaching the renal survival end point (eTable 3 and model 1 in eTable 4 in the Supplement). The serum suPAR concentration contributed to the model (model 2 in eTable 4 in the Supplement) after adjustment for age, proteinuria, blood pressure, and renal diagnosis, but this association lost significance when initial eGFR was included in the model (model 3 in eTable 4 in the Supplement).
To determine whether the association between suPAR level and the outcome varied according to baseline eGFR, we performed sensitivity analysis using different baseline eGFR cutoff levels (30, 35, 40, 45, and 50 mL/min/1.73 m 2 ). We found significant interaction between suPAR level and eGFR for the cutoff values 30, 35, and 40 mL/min/1.73 m 2 ; the highest hazard ratio was observed for the 40 mL/min/1.73 m 2 cutoff (Figure 2) . None of the other covariates, including age, sex, diagnosis, or proteinuria, showed a significant interaction with respect to the association of high suPAR levels with the risk of reaching the renal survival end point (Figure 2) . Based on the observed eGFR dependence of the predictive value of suPAR levels, we performed a subgroup analysis using patients with an eGFR greater than 40 mL/min/1.73 m 2 . In this subgroup, proteinuria, glomerular disease, and initial eGFR were associated with a poor outcome (model 1 in Table 2 and Table 3 ). In addition to these factors, the circulating suPAR level was highly significantly associated with renal risk (Table 2 ). Accounting for both eGFR and log suPAR concentrations improved the information content of the model from an AIC of 387 Q4   224  166  140  124  83  193  224  141  116  81  53  183  225  155  120  98  62  186  225  120  83  62  46  163 Five-year renal survival probability in children with CKD is plotted according to suPAR quartile. Q1 indicates a suPAR level less than 4.610 pg/mL; Q2, 4.610-5.658 pg/mL; Q3, 5.658-7.053; Q4, greater than 7.053. Q1 is the lowest quartile and Q4 is the highest quartile.
(for models including either eGFR or log suPAR) to an AIC of 381 (Table 3 ). Comparing the ratio of Akaike weights (0.909 vs 0.053) of model 3 with model 1 indicates that model 3 is 17.3-fold more likely to be the best model in the AIC sense. In other words, the combined use of eGFR and suPAR level in the model was associated with a 17.3-fold lower likelihood of information loss than the use of either eGFR alone or suPAR level alone.
Discussion
This report demonstrates that serum suPAR level is associated with a more rapid decline in kidney function in pediatric patients with mild to moderate CKD at risk of progressive renal failure, independent of the established risk markers eGFR and proteinuria and across a large variety of underlying kidney diseases. To our knowledge, this is the first documentation of an association between suPAR level and loss of kidney function in children and adolescents. Given the difference between the origin of pediatric and adult kidney diseases, it was reassuring that our findings complement recent work in adult populations that associated high suPAR levels with an increased risk of developing CKD.
11-13 Children with CKD represent a unique population for studies of disease progression owing to the virtual absence of confounding secondary pathologies related to factors, such as diabetes, hypertension, smoking, and aging. This allows for more sensitive assessments of biomarkers and risk factors linked to renal disease progression. The coverage of a wide eGFR range allowed us to study the association between suPAR levels and CKD progression relative to the prevailing degree of renal dysfunction. In prospective CKD studies, GFR is universally highly predictive of renal survival because the time to both end-stage renal disease and a fractional GFR loss is shorter in patients with an initially low GFR. Owing to impaired clearance of suPAR in advanced CKD, an inverse relationship between circulating suPAR levels emerges as renal failure progresses, limiting the additional information content of suPAR levels over eGFR alone. It remains to be explored whether the usefulness of suPAR level measurement in advanced CKD can be improved by concurrent assessment of suPAR binding and activation of its receptor on podocytes, ie, β3-integrin. 10, 18, 20, 21 On the other hand, suPAR has recently been demonstrated to be a sensitive predictor of early kidney damage and progression to CKD in adults. [11] [12] [13] 22 In this study, we provide evidence that (1) suPAR level is associated with CKD progression throughout the eGFR range from 15 to 80 mL/ min/1.73 m 2 , and (2) the strength of the association with suPAR exceeds that of eGFR alone in patients with mild to moderate . The association between suPAR level and the rate of decline in kidney function was independent of the presence of significant proteinuria, the other well-established risk marker of CKD progression. Hence, suPAR level has the potential to become a clinically useful marker for risk stratification in patients with mild to moderate CKD (stage 3), the critical phase when secondary complications of CKD start to develop and nephroprotective interventions may be most effective.
Another important observation was the independence of the association of suPAR concentrations with CKD progression of the underlying kidney disease. Chronic kidney disease in children is predominantly caused by congenital renal malformations and hereditary kidney disorders, in striking contrast to the adult population, where CKD in most individuals is secondary to diabetes, hypertension, immunoglobulin A nephropathy, or aging. Whereas adult CKD usually originates from glomerular pathology, more than 70% of the pediatric CKD cohort studied here originated from congenitally reduced functioning nephron mass, with another 10% from primary tubulointerstitial disorders, and only 7% of our study population had primary glomerular disease. Despite the differences in etiology, children and adults with CKD exhibit similar rates of progression.
Soluble urokinase receptor belongs to the lysine-6/uPAR/ α-neurotoxin family of signaling proteins and was originally identified as a circulating factor in glomerular disorders. 10 Our findings that eGFR-adjusted suPAR levels were similar across the disease groups and that suPAR level was associated with the trajectory of kidney function over time regardless of the underlying disease imply that its predictive value is not limited to glomerular disease. Soluble urokinase receptor is known to be produced by bone marrow-derived immature myeloid cells, and in preclinical studies, it contributes to systemic forms of kidney disease commonly associated with proteinuria. 23 In animal models, animals with elevated suPAR levels develop renal disease, 10, 23, 24 and one can speculate about potential sites of involvement of suPAR along the nephron. For example, suPAR binds to and activates β3-integrins and triggers alterations in podocyte structure and function. 10, 25, 26 Whether suPAR acts in the tubulointerstitium to promote fibrosis in individuals with congenital anomalies or primary tubulointerstitial diseases requires further study. The mean suPAR level in our cohorts was often several-fold higher than levels measured in children with normal weight or obesity, 27 and it was comparable with or higher than in adults who will develop kidney disease. Also, suPAR levels tended to decrease with patient age. We speculate that a more active innate immune system in childhood may lead to higher suPAR levels.
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Strengths and Limitations
The strengths of this study are the large numbers of pediatric patients enrolled in 2 high-quality clinical studies. The population encompasses a wide range of underlying renal diseases, age, and eGFR and represents a diversity of racial/ethnic backgrounds, macroeconomic factors, and health care systems across 13 European countries. Patients were comprehensively phenotyped over time so that the longitudinal data on GFR are likely to be accurate. The composite renal survival end point in this study represents a hard clinical outcome consistent with the standard that the US Food and Drug Administration applies to assess the efficacy of novel therapeutic interventions. The limitations of this study include measurement of suPAR levels at a single time, the lack of African American and Asian individuals, and the lack of complete clinical information to eliminate residual confounding factors (eg, smoking, environmental exposures, and birth weight). Finally, because our patient population consisted of patients with established CKD, we are unable to derive conclusions on the usefulness of suPAR level as a predictive marker in patients at risk for or in very early stages of CKD.
Conclusions
In conclusion, our findings demonstrate that an elevated serum suPAR level is associated with increased risk of deterioration in kidney function in children with mild to moderate CKD (eGFR, 40-80 mL/min/1.73 m 2 ) secondary to a broad range of 
